Last reviewed · How we verify
NCT04611425: REHSCU
REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study
Phase 2 trial testing Remimazolam in Acute Respiratory Failure in 30 participants. Completed in 22 October 2021.
2 December 2020
Quick facts
| Lead sponsor | Nantes University Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 30 |
| Start date | 30 November 2020 |
| Primary completion | 2 December 2020 |
| Estimated completion | 22 October 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Remimazolam — full drug profile →
Conditions studied
- Acute Respiratory Failure — all drugs for Acute Respiratory Failure →
- COVID-19 — all drugs for COVID-19 →
- Trauma — all drugs for Trauma →
- Stroke — all drugs for Stroke →
Sponsor
Nantes University Hospital
Who can join
Adults 18 to 85, any sex, with Acute Respiratory Failure or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The worldwide COVID-19 pandemic has led to a dramatic increase in the number of patients hospitalized in intensive care units for an acute respiratory failure in all countries. This situation has quickly led to massive shortage in masks, mechanical ventilation machines and common medications such as hypnotics. All countries over the world are currently experiencing a major shortage in basic hypnotic medications (propofol, midazolam) in the intensive care as well as in the operating theatre. The Principal Investigator proposes to perform a pilot study assessing the benefit-risk ratio of Remimazolam (a novel benzodiazepine with a short half-life) in the critical care units of Nantes University Hospital during the COVID-19 pandemic.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Remimazolam: pharmacological characteristics and clinical applications in anesthesiology.
Kim KM. · · 2022 · cited 161× · PMID 35139608 · DOI 10.17085/apm.21115 -
Review of remimazolam and sedatives in the intensive care unit.
Choi HR, Song IA. · · 2022 · cited 9× · PMID 35698764 · DOI 10.4266/acc.2022.00619 -
A phase 2 open-label pilot study of Remimazolam for sedation in critically ill patients.
Grillot N, Vourc'h M, Hourmant Y, Bouras M, et al · · 2025 · cited 3× · PMID 40174701 · DOI 10.1016/j.accpm.2025.101510
Verify or expand the search:
- PubMed search for NCT04611425
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remimazolam
Trials testing the same drug.
- NCT07251101 — Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery · NA · not yet recruiting
- NCT07459322 — The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy · NA · not yet recruiting
- NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
- NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting
Other recruiting trials for Acute Respiratory Failure
Currently open trials in the same condition.
- NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
- NCT06912360 — Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso · NA · recruiting
- NCT06876168 — Virtual Reality in ICU - PARTNER · recruiting
- NCT06952816 — Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure · NA · recruiting
- NCT06934876 — Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adul · recruiting
Other Nantes University Hospital trials
Trials by the same sponsor.
- NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
- NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
- NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611425 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
- Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611425.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing